Peptide Association
Start Your Consultation
All peptides
MetabolicIn Clinical Trials

Amycretin

Subcutaneous injection
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

Amycretin is a dual agonist targeting both the amylin and calcitonin receptors, designed as a peptide therapeutic for obesity. Amylin receptor activation reduces food intake and delays gastric emptying, while calcitonin receptor engagement may further contribute to appetite suppression and weight loss.

Mechanism of Action

The compound represents a novel approach distinct from GLP-1-based therapies.

Research Summary & Key Findings

Early-phase clinical data released in 2023 indicated dose-dependent weight loss in individuals with obesity. The safety profile was acceptable, with nausea being the most frequently reported adverse event. Further trials are needed to determine long-term efficacy and optimal dosing.

Clinical Status

In Clinical Trials

Amycretin is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Subcutaneous injection

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Metabolic

Semaglutide (Ozempic/Wegovy)

FDA Approved

A glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...

View details

Tirzepatide (Mounjaro/Zepbound)

FDA Approved

A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activat...

View details

Retatrutide

In Clinical Trials

An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The gluc...

View details

AOD-9604

Investigational

A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...

View details

Start Your Consultation

Get an AI-proposed Amycretin protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Amycretin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.